Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome)

被引：15

作者：

Dimopoulos, Spyridon ^{[1
]}

Deuter, Christoph M. E. ^{[1
]}

Blumenstock, Gunnar ^{[2
]}

Zierhut, Manfred ^{[1
]}

Dimopoulou, Anastasia ^{[1
]}

Voykov, Bogomil ^{[1
]}

Bartz-Schmidt, Karl-Ulrich ^{[1
]}

Doycheva, Deshka ^{[1
]}

机构：

[1] Univ Hosp Tuebingen, Ctr Ophthalmol, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany

[2] Eberhard Karls Univ Tuebingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2020年 / 28卷 / 02期

关键词：

Cataract surgery; interferon alpha; Irvine-Gass syndrome; macular edema; treatment; RISK-FACTORS; SURGERY; PHACOEMULSIFICATION;

D O I：

10.1080/09273948.2019.1585883

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To assess the efficacy and safety of systemic interferon alpha-2a (IFN) for refractory pseudophakic cystoid macular edema (PCME). Methods: Retrospective observational study. The primary outcome was the decrease of central retinal thickness (CRT). Secondary endpoints were the improvement of best-corrected visual acuity (BCVA) and the assessment of IFN-related side effects. Results: Twenty-four eyes of 20 patients were included. The median CRT was 513 mu m (range 220-980 mu m) at baseline and decreased to 190 mu m (range 140-520 mu m) at the last follow-up visit (p < 0.001). Reduction of CRT greater than 100 mu m was observed in 22 eyes (92%). The median BCVA (logMAR) increased statistically significant from 0.5 (range 0.2-1.5) at baseline to 0.3 (0-0.8) at the last follow-up (p < 0.001). The BCVA improved in 18 eyes (75%) and remained stable in five eyes (21%). No severe treatment-related side effects occurred. Conclusion: IFN is a very effective agent for treatment of refractory PCME.

引用

页码：315 / 321

页数：7

共 50 条

[21] Grid laser photocoagulation for macular oedema in uveitis or the Irvine-Gass syndrome
Lardenoye, CWTA
van Schooneveld, MJ
Treffers, WF
Rothova, A
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (09) : 1013 - 1016
[22] Intravitreal triamcinolone for refractory pseudophakic cystoid macular edema
Nelson, ML
Martidis, A
Spinak, DJ
Liu, M
Sivalingam, A
Federman, JL
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U40 - U40
[23] FACTORS OF PROGNOSIS IN IRVINE-GASS SYNDROME
BONNET, M
ANNALES D OCULISTIQUE, 1975, 208 (04): : 275 - 278
[24] Is first eye pseudophakic (Irvine-Gass) cystoid macular edema (CME) an independent risk factor for CME in the second eye? Results from a large retrospective 3 centre study
Halim, Jonathan
Cascone, Nikhil
Coombes, Andrew
Westcott, Mark
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[25] Very late onset Irvine-Gass syndrome
Jakob-Girbig, J.
Hahner, L.
Meller, D.
OPHTHALMOLOGE, 2021, 118 (12): : 1267 - 1271
[26] Pseudophakic cystoid macular edema
Yonekawa, Yoshihiro
Kim, Ivana K.
CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (01) : 26 - 32
[27] Pseudophakic cystoid macular edema
Fouad, Yousef A.
Karimaghaei, Sam
Elhusseiny, Abdelrahman M.
Alagorie, Ahmed R.
Brown, Andrew D.
Sallam, Ahmed B.
CURRENT OPINION IN OPHTHALMOLOGY, 2025, 36 (01) : 62 - 69
[28] Pseudophakic cystoid macular edema
Radeck, Viola
Maerker, David
Prahs, Philipp
Helbig, Horst
Krause, Lothar
OPHTHALMOLOGE, 2020, 117 (06): : 579 - 590
[29] Pseudophakic Cystoid Macular Edema
Lobo, Conceicao
OPHTHALMOLOGICA, 2012, 227 (02) : 61 - 67
[30] IRVINE-GASS SYNDROME - STATISTICAL AND FLUORESCEIN ANGIOGRAPHYSTUDY
BALTAZIS, S
THEODOSSIADIS, G
VELISSAROPOULOS, P
ARCHIVES D OPHTALMOLOGIE, 1976, 36 (01): : 21 - 32

← 1 2 3 4 5 →